Pakistanis angry over detentions in Times Sq. case Monday, May 24, 2010
ISLAMABAD – Relatives of three men detained by Pakistan for alleged links to the suspect in the attempted Times Square bombing say the men are innocent.
They
AFP - Thursday, August 6TAIPEI (AFP) - - Taiwan's Beijing-friendly government on Wednesday denied boycotting an Australian film festival amid a row over the e
BERLIN (Reuters) - Chancellor Angela Merkel suffered a double blow on Thursday as a senior party ally in east German
Minister seeks closure of anti-Berlusconi websites Wednesday, December 16, 2009
ROME (AFP) - – The Italian government moved Tuesday to close down Internet sites encouraging further violence against Prime Minister Silvio Berlusconi, who
By ELAINE KURTENBACH,AP Business Writer AP - Wednesday, March 18SHANGHAI - Asia's stock market rally seemed to be running out of steam Wednesday, despite an
Edition:
U.S.
Africa
Arabic
Argentina
Brazil
Canada
China
France
Germany
India
Italy
Japan
Latin America
Mexico
Russia
Spain
United Kingdom
Home
Business
Business Home
Economy
Technology
Media
Small Business
Legal
Deals
Earnings
Social Pulse
Business Video
The Freeland File
Aerospace & Defense
Investing Simplified
Markets
Markets Home
U.S. Markets
European Markets
Asian Markets
Global Market Data
Indices
M&A
Stocks
Bonds
Currencies
Commodities
Futures
Funds
peHUB
Dividends
World
World Home
U.S.
Brazil
China
Euro Zone
Japan
Mexico
Russia
India Insight
World Video
Reuters Investigates
Decoder
Politics
Politics Home
Election 2012
Campaign Polling
Supreme Court
Politics Video
Tech
Technology Home
MediaFile
Science
Tech Video
Tech Tonic
Social Pulse
Opinion
Opinion Home
Chrystia Freeland
John Lloyd
Felix Salmon
Jack Shafer
David Rohde
Nader Mousavizadeh
Lucy P. Marcus
Nicholas Wapshott
Bethany McLean
Anatole Kaletsky
Edward Hadas
Hugo Dixon
Ian Bremmer
Lawrence Summers
Susan Glasser
The Great Debate
Steven Brill
Reihan Salam
Frederick Kempe
Christopher Papagianis
Mark Leonard
Breakingviews
Equities
Credit
Private Equity
M&A
Macro & Markets
Politics
Breakingviews Video
Money
Money Home
Tax Break
Lipper Awards 2012
Global Investing
MuniLand
Unstructured Finance
Linda Stern
Mark Miller
John Wasik
James Saft
Analyst Research
Alerts
Watchlist
Portfolio
Stock Screener
Fund Screener
Personal Finance Video
Money Clip
Investing 201
Life
Health
Sports
Arts
Faithworld
Business Traveler
Entertainment
Oddly Enough
Lifestyle Video
Pictures
Pictures Home
Reuters Photographers
Full Focus
Video
Reuters TV
Reuters News
Article
Comments (1)
Pictures
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Hurricane Sandy
The aftermath of Hurricane Sandy. Slideshow
Halloween: Before and after
Before and afters from a Halloween Horror Party in Germany. Slideshow
Follow Reuters
Facebook
Twitter
RSS
YouTube
Read
Death toll up, gasoline lines grow in monster storm's wake
|
10:25am EDT
Vatican may eventually limit Sistine Chapel visits
31 Oct 2012
Obama to use "affirmative" message in closing pitch
4:45am EDT
Republican candidate calls aborting rapist's child "more violence on woman's body"
12:42am EDT
Republican candidate calls aborting rapist's child 'more violence on woman's body'
12:41am EDT
Discussed
93
Race is tied, but most think Obama will win: Reuters/Ipsos poll
87
Analysis: U.S. presidential race is all about Ohio – or is it?
67
Obama votes, picks up Powell endorsement amid swing state push
Sponsored Links
Insight: Crunching the numbers to boost odds against cancer
Tweet
Share this
Email
Print
Related News
Microsoft highlights Surface at Windows 8 launch
Thu, Oct 25 2012
Biogen third-quarter profit rises, as does 2012 forecast
Thu, Oct 25 2012
UPDATE 3-SAP software sales top forecast as wins market share
Wed, Oct 24 2012
Abbott says kidney drug study halted; shares drop
Thu, Oct 18 2012
Microsoft profit slips as PCs fizzle; Windows 8 awaited
Thu, Oct 18 2012
Analysis & Opinion
Declare victory in the war on drugs – then run like hell
Free and Open Data as a Worldwide Economic Engine
Related Topics
Health »
Tech »
Media »
Sandy in photos
The aftermath of Sandy showcased in a series of large format pictures. Full Article
A dispensing chemist prepares drugs for a chemotherapy treatment in a sterile room at Antoine-Lacassagne Cancer Centre in Nice October 18, 2012. Picture taken October 18, 2012.
Credit: Reuters/Eric Gaillard
By Ludwig Burger
FRANKFURT |
Thu Nov 1, 2012 11:15am EDT
FRANKFURT (Reuters) - Software engineers are moving to the fore in the war on cancer, designing programmes that sift genetic sequencing data at lightning speed and minimal cost to identify patterns in tumors that could lead to the next medical breakthrough.
Their analysis aims to pinpoint the mutations in our genetic code that drive cancers as diverse as breast, ovarian and bowel. The more precise their work is, the better the chance of developing an effective new drug.
Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are. The confluence of computing and medicine is accelerating the pace of genetic research.
But making sense of the swathes of data has become a logjam.
That, in turn has created an opportunity for computer geeks and tech firms such as Microsoft, SAP and Amazon.
Oncology is the largest area of therapy in the global drugs market with market researcher IMS predicting it will increase to $83-$88 billion by 2016 from $62 billion in 2011. Computational genomics - using computers to decipher a person's genetic instructions and the mutations in cancerous cells - is emerging as the driver of this growth.
Life Technologies Corp and Illumina Inc are among firms developing equipment that can extract a person's entire genetic code - their genome - from a cell sample.
The newest machines are about the size of an office printer and can sequence a genome in a day, compared with six to eight weeks a few years ago. They can read the 3.2 billion chemical "bases" that make up the human genetic code for $1,000, compared with $100,000 dollars in 2008.
Growing numbers of software engineers are needed to help make sense of all this data.
"Many labs can now generate the data but fewer people or labs have the expertise and infrastructure to analyze it - this is becoming the bottleneck," said Gad Getz, who heads the Cancer Genome Analysis group at the Broad Institute in Boston, jointly run by MIT and Harvard.
Getz is one of a new generation of computational biologists who develop algorithms to parse data from tens of thousands of cell samples, shared with research institutes around the globe.
He and his team of 30 are trying to establish recurring patterns in the mutations and how they are linked to tumor growth. They are using some 1,200 processing units, each with 4-8 gigabytes of random access memory - about the computing power that comes with most desktop PCs.
HARVESTING KNOWLEDGE
Eli Lilly CEO John Lechleiter sees potential for progress.
"We are starting to harvest the knowledge that we gained through the sequencing of the human genome, our understanding of human genetics, disease pathways. We've got new tools that we can use in the laboratory to help us get to an answer much, much faster," said Lechleiter, whose firm is co-owner of the rights to bowel cancer drug Erbitux.
Approved drugs that take genetic information into account include Amgen's Vectibix and AstraZeneca's Iressa. But both these drugs derive from a single mutation. Sequencing has laid bare many more mutant genes - often hundreds in any given tumor - and highlighted the need for a subtler approach to cancer treatment.
Roche, the world's largest maker of cancer medicines, has spent several million euros on information technology for a pilot scheme examining how cancer cells in petri dishes react to new drugs. The scheme involves crunching hundreds of terabytes of gene sequences.
"It's the first large-scale in-house sequencing project for Roche and we expect more to follow in the near future," said Bryn Roberts, Roche's head of informatics in drug research and early development.
Roberts said the project, which uses processing power equivalent to hundreds of high-end desktop PCs, was self contained but there were plans to draw in external data. This would require advances in cloud computing - using software and computing power from remote data centers - but Roberts said the technology would soon be available.
"The scale of the problem means the solution will be on an international collaborative scale," he said.
OPPORTUNITIES IN CLOUDS
The trend of using cloud computing networks to allow commercial and public researchers to share cancer data is promising for the likes of IBM and Google which according to GBI Research are already established providers of cloud computing to drug makers' research efforts.
Amazon, with its cloud computing unit AWS, said it is benefiting as life science researchers rethink how data is stored, analyzed and shared. "We are happy with the growth we are seeing," a spokesman said, declining to provide figures.
Microsoft said it was dedicating "significant resources" to the expansion of cloud computing in the health and life sciences markets.
"Pharma R&D will be working with other technology companies, like Microsoft, in developing new algorithms, methodologies and indeed even therapies themselves," said Les Jordan, chief technology strategist at Microsoft's Life Sciences unit.
The world's largest business software company SAP has teamed up with German genetic testing specialist Qiagen. They are modifying SAP database software so that certain cancer diagnostic tests, which now keep a network of super computers busy for days, can be run on a desktop PC within hours.
Genetic analysis has revealed that types of cancer, now treated as one because they are in the same organ and look the same under the microscope, are driven by different genetics.
Hans Lehrach at the Max Planck Institute for Molecular Genetics in Berlin says every single tumor should be seen as an "orphan disease", using a term for rare illnesses that typically prompt drug regulators to make drug approval easier.
He has designed a software he describes as a virtual patient. It suggests a drug or a mix of drugs based on each tumor's genetic fingerprint. A single case can take several days to be processed.
Lehrach, a geneticist who says he has written software code throughout his scientific career, likens his approach to that of a meteorologist who regards every day's set of readings as unique.
Taking the analogy further, he says the convention of stratifying cancer patients is equivalent to a weather forecast based on simple rules such as 'red sky in the morning, sailor take warning'.
At a unit of Berlin's Charite university hospital, 20 patients left with no other treatment options for their aggressive type of skin cancer are being diagnosed based on Lehrach's computer model.
The trial is exploratory and there are no results yet on the overall treatment success, but the project, like many others, is driven by the hope that cancer can be wrestled down by sheer computing power.
(Additional reporting by Stephanie Nebehay; editing by Janet McBride)
Health
Tech
Media
Related Quotes and News
Company
Price
Related News
Tweet this
Link this
Share this
Digg this
Email
Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
minutemanII wrote:
Edition:
U.S.
Africa
Arabic
Argentina
Brazil
Canada
China
France
Germany
India
Italy
Japan
Latin America
Mexico
Russia
Spain
United Kingdom
Back to top
Reuters.com
Business
Markets
World
Politics
Technology
Opinion
Money
Pictures
Videos
Site Index
Legal
Bankruptcy Law
California Legal
New York Legal
Securities Law
Support & Contact
Support
Corrections
Connect with Reuters
Twitter
Facebook
LinkedIn
RSS
Podcast
Newsletters
Mobile
About
Privacy Policy
Terms of Use
AdChoices
Copyright
Our Flagship financial information platform incorporating Reuters Insider
An ultra-low latency infrastructure for electronic trading and data distribution
A connected approach to governance, risk and compliance
Our next generation legal research platform
Our global tax workstation
Thomsonreuters.com
About Thomson Reuters
Investor Relations
Careers
Contact Us
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.